Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ASKB589

Phase 2Small molecule

AAskGene Pharma, Inc.

ASKB589 is one of 22 small molecule programs targeting PD-1 Inhibitors. It is currently in Phase 2.

2

Indications

3

Total Trials

3

Active Trials

21

Competitors

Pipeline

Status by Indication[3][1]

Indication

PD-1 InhibitorsActive, not recruiting

Locally Advanced or Metastatic Solid TumorsActive, not recruiting

PD-1 InhibitorsPhase 2

Active, not recruiting

Locally Advanced or Metastatic Solid TumorsPhase 2

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Locally Advanced or Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Tecentriq

Keytruda

Afinitor

Vitrakvi

Stivarga

OPDUALAG

Bristol-Myers Squibb

Cabometyx

Bristol-Myers Squibb

Budigalimab

Livmoniplimab

N-803

IImmunityBio, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Active, not recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06206733

Clinical

Trials by Indication[1]

Locally Advanced or Metastatic Solid Tumors1 trial

A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting·JJiangsu Aosaikang Pharmaceutical Co., Ltd.·Phase 1/2·NCT04632108·199 enrolled

PD-1 Inhibitors1 trial

ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

Active, not recruiting·AAskGene Pharma, Inc.·Phase 1/2·NCT05632939·62 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

A Phase III Study Evaluating the Efficacy and Safety of ASKB589 Combined With CAPOX and PD-1 Inhibitor as First-Line Treatment in Claudin18.2 Positive Patients With Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Active, not recruiting·AAskGene Pharma, Inc.·Phase 3·NCT06206733·780 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ASKB589. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ASKB589 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ASKB589. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AskGene Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAskGene Pharma, Inc.

Related News